Angiosarcoma Of Scalp Research Articles

Survival Analysis of Scalp Angiosarcoma Patients for Treatment Modalities in our Hospital Over the Past 28 Years

Background: Angiosarcoma is a malignant neoplastic disease that often occurs in older people. The prognosis is poor and treatment effectiveness remains controversial. Objective: We examined cases of scalp angiosarcoma treated in Nagoya City University Hospital from 1985 to 2013 and retrospectively analyzed treatment effectiveness. Methods and materials: We identified 21 scalp angiosarcoma patients and followed up 18 patients among them. Disease-specific survival was calculated by the Kaplan and Meier method and compared between treatments. Results: Median patient age was 75 years, and 14 patients (78%) were over 70 years of age. The 2- and 5-year disease-specific survival was 62.7% and 26.3%, respectively. Overall survival was significantly longer in those receiving radiotherapy or combination therapy with radiotherapy and chemotherapy. Thirteen patients (72%) received chemotherapy and 12 patients received taxane-based chemotherapy. Although toxicity occurred in 11 patients receiving taxane-based chemotherapy, most cases were grade 1 or 2. Conclusions: Combination therapy with radiotherapy and taxane-based chemotherapy may be an effective medical treatment for scalp angiosarcoma, and can be performed safely even in older patients

頭皮原発血管肉腫の肺転移により続発性気胸を生じた1例

頭皮原発血管肉腫の肺転移により続発性気胸を生じた1例

血管肉腫肺転移による難治性気胸の一手術例

症例は76歳男性．某年5月に頭皮の血管肉腫に対して外科的治療が行われた．翌年1月に他院で両側気胸に対して右胸腔鏡下生検が行われ血管肉腫の肺転移と診断され，当院緩和ケア病棟に入院となった．その後右気漏が残存したため，胸腔鏡下に右肺瘻閉鎖術を施行した．気漏部位を連続縫合と自動縫合器で閉鎖しポリグリコール酸シートを用いて補強した．術後5日目に右胸腔ドレーンを抜去し，術後21日目に退院となった．術後36日目に左気胸が再燃し緩和ケア病棟に再入院した．血胸，肺出血を併発し術後91日目に死亡退院となった．肺転移から続発する気胸は内科的治療による改善が難しく，緩和治療においてもドレーンによる創痛や行動制限の原因となる．長期間病状が安定している場合外科的な肺瘻閉鎖を検討すべきであり，緩和的意義もあると考えられた．

Scalp Angiosarcoma Presented as Skin-coloured Papules

Scalp Angiosarcoma Presented as Skin-coloured Papules

A case of metastatic scalp angiosarcoma presenting as multiple thin-walled lung cysts and pneumothorax

A case of metastatic scalp angiosarcoma presenting as multiple thin-walled lung cysts and pneumothorax

Cutaneous versus Non-Cutaneous Angiosarcoma: Clinicopathologic Features and Treatment Outcomes in 60 Patients at a Single Asian Cancer Centre

Background: Angiosarcoma (AS) is an uncommon soft tissue sarcoma with dismal prognosis that presents either cutaneously (C-AS) or non-cutaneously (NC-AS). We compared the clinical features and treatment outcomes between these 2 groups. Methods: A single-centre study evaluating 60 AS patients between 2002 and 2012 was performed. Results: The median age was 70 years. C-AS of the scalp or face comprised 66% of patients. C-AS patients were older than NC-AS (median age 74 vs. 56 years; p < 0.001). Proportionately more C-AS patients presented with non-metastatic disease (86 vs. 50%; p = 0.007). Amongst resected C-AS and NC-AS patients, rates of positive surgical margins (53 vs. 50%; p = 1.00) and adjuvant therapy (25 vs. 43%; p = 0.626) were not significantly different, though proportionately fewer C-AS patients relapsed (36 vs. 78%; p = 0.038). Paclitaxel was the most common agent in first line palliative systemic therapy, achieving an objective response rate of 56%. Median overall survival was 11.2 months, with no significant difference between C-AS and NC-AS (11.3 vs. 9.8 months; p = 0.895). Conclusion: Distinct from AS in the West, our series demonstrates a clear preponderance of scalp AS. Disparities in clinical characteristics between C-AS and NC-AS did not translate into survival differences.

Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature.

Bevacizumab, an angiogenesis inhibitor, is a recombined humanized monoclonal antibody against vascular endothelial growth factor and a promising therapeutic option for angiosarcoma management. This is a case report and review of the literature using bevacizumab and combination chemotherapy for angiosarcoma. The understanding of the effectiveness of combined therapy of bevacizumab and chemotherapy agents is still limited. The benefits of bevacizumab treatment for angiosarcoma will need to be weighed against the risks of venous thromboembolism in this population.

An Uncommon Profile of a Case of Angiosarcoma of Scalp and Face

Angiosarcoma is a rare soft tissue sarcoma usually seen in the head, face and neck [1]. Head and neck angiosarcomas are seen in elderly population with the mean age greater than 60 years [2]. Angiosarcoma also has a slight predilection for Caucasian patients and the male gender. The estimated ratio of male-to-female predominance is approximately 3:1. Angiosarcoma involving the scalp of old patients was first described as a distinct subgroup by Wilson-Jones and is usually limited to the skin and soft tissues. The disease occurs in the dermis and presents as single or multiple bluish or red nodules or plaques which ulcerate or bleed. Metastasis to regional lymph nodes or lungs can occur [4].

A Case of Scalp Angiosarcoma with Lung Metastases Presenting as Multiple Thin-walled Cysts

A Case of Scalp Angiosarcoma with Lung Metastases Presenting as Multiple Thin-walled Cysts

Impact of Chemoradiation Therapy Using Docetaxel for Treatment of Scalp Angiosarcoma

Impact of Chemoradiation Therapy Using Docetaxel for Treatment of Scalp Angiosarcoma

Pneumothorax: A Classical Presentation of Metastatic Scalp Angiosarcoma

Metastatic pulmonary angiosarcomas frequently present with pneumothorax, especially those arising from the scalp. The metastases on chest radiographs are initially subtle and easily missed. Computed tomographic scans can show a spectrum of diagnostic findings that may be misinterpreted because of a lack of awareness related to the rarity of the disease. We report a patient who presented with pneumothorax and lung cysts before his primary scalp angiosarcoma was diagnosed. This case highlights the sometimes ominous nature of innocuous-looking, thin-walled cystic pulmonary lesions.

Angiosarcoma of the scalp diagnosed by the presence of neck inflammation: a case report

Angiosarcoma is an uncommon malignancy, which spread out from the endothelial cells of vessels. Scalp angiosarcoma with cervical lymph node metastasis is particularly rare. This article describes a rare case of angiosarcoma of the scalp, presenting as neck inflammation. Imaging procedures such as computed tomography (CT), magnetic resonance image (MRI) and ultrasonography (US) were not sufficient to diagnose this case. A needle biopsy provided an effective and accurate diagnosis of cervical lymph node metastasis. Additional observation and physical examination was required to diagnose the origin of the primary cancerous lesion. Once the angiosarcoma diagnosis was confirmed histologically, sequential weekly and monthly docetaxel (DTX) treatment was effective in preventing reoccurrence. Nonetheless, the optimization of angiosarcoma treatment remains a future goal. Although patients generally describe pain and swelling at the primary lesion site, this patient complained only of painful neck inflammation, without any indication of pain or swelling of the scalp. A revised diagnostic protocol should note that cervical lymph node metastasis of unknown primary origin may result from angiosarcoma of the scalp.

Angiosarcoma of the Scalp Successfully Treated With a Single Therapy of Sorafenib

Angiosarcoma (AS) of the scalp is a rare and aggressive neoplasm with one of the worst prognoses among malignant skin tumors. The overall 5-year survival rate is less than 30%. Specific treatment guidelines are absent, and treatment options include surgical excision, radiation therapy, chemotherapy (CT), and biological therapy such as recombinant interleukin 2 (rIL-2). Surgical excision with negative margins combined with CT is the most successful strategy for improving the prospect for survival. Considering that (1) the age range of patients with AS of scalp and face is 70 to 75 years; that (2) the strong toxicity of current first-line CTs, including taxanes, often requires treatment cessation; and that (3) tumors gradually become unresponsive during the course of treatment in many cases, patients with AS require a new, effective, and safe treatment. Sorafenib inhibits KIT, FLT-3, VEGFR-1, 2, 3, and PDGFRin a dose-dependent manner. Recently, a multicenter phase 2 study found that single-agent sorafenib was safe and especially active against recurrent and metastatic AS. Progression-free survival and overall survival rates were 3.8 months and 14.9 months, respectively. The study recommended sorafenib, 400 mg twice daily, for AS.

頭皮血管肉腫と同時に発見された薄壁空洞を呈した肺癌の1例

頭皮血管肉腫と同時に発見された薄壁空洞を呈した肺癌の1例を報告する．症例は，頭皮血管肉腫を罹患した51歳男性で，同時に左肺下葉に，壁厚1 mm，6×8 mm大の薄壁空洞を主体とする腫瘤を認めた．頭皮血管肉腫の完全切除後，血管肉腫の肺転移と判断し，術後治療としてテセロイキンという遺伝子組み換えIL-2製剤投与にて経過観察された．その後6年間の加療中，肺病変以外の血管肉腫の再発を認めなかったが，肺病変が徐々に増大するため，診断と治療を兼ねて手術を施行し，原発性肺腺癌と診断された．肺の空洞性病変には，あらゆる肺疾患の可能性がある．空洞性の転移性肺病変を呈し得る疾患と同時に肺病変が発見された際には,慎重な経過観察が必要で，転移性病変として合致しない経過を示した際には，時機を逸さずに外科的生検を試みる必要がある．

Scalp Angiosarcoma Remission with Bevacizumab and Radiotherapy without Surgery: A Case Report and Review of the Literature

Angiosarcoma (AS) is a rare and aggressive vascular neoplasm with very poor prognosis. Patients with extensive cutaneous AS who are not surgical candidates have very limited options since there is no standard treatment. Treatment options include radiation, chemotherapy, and angiogenesis inhibitor with varying success rates. Here, we report a case an 88 year old patient with extensive scalp angiosarcoma having biopsy proven remission with bevacizumab and radiotherapy without undergoing surgery.

80歳以上の高齢者における頭部脈管肉腫2症例に対する化学療法

80歳以上の高齢者における頭部脈管肉腫2症例に対する化学療法

Surgical Treatment of Angiosarcoma of the Scalp With Superficial Parotidectomy

Angiosarcomas of the scalp area are rare tumors mostly affecting elderly patients. In many series, potential treatment options for patients with scalp angiosarcoma have included surgery, radiation, and chemotherapy. Surgery combined with radiation therapy, however, did not appear to cure many patients. For these reasons, there is a serious need for the development of new approaches. We report our experience of 8 patients presenting angiosarcoma solely of the scalp. Our procedure consisted in radical tumor resection of the scalp with minimal 5-cm safety margins from the most peripheral scatted lesions with burring of the external table of the cranium, ipsilateral superficial parotidectomy, and ipsilateral upper neck dissection. After resection of the tumor of the scalp, the latissimus dorsi free flap was used for coverage of the defect. With prophylactic dissection of these regional lymph nodes, we could achieve better results and, at least, prolonged time to local recurrence and distant metastasis.

Angiosarcoma of the scalp. Extent study with PET-CT

Angiosarcoma of the scalp. Extent study with PET-CT

A novel splice variant of the DNA-PKcs gene is associated with clinical and cellular radiosensitivity in a patient with xeroderma pigmentosum

BackgroundRadiotherapy-induced DNA double-strand breaks (DSBs) are critical cytotoxic lesions. Inherited defects in DNA DSB repair pathways lead to hypersensitivity to ionising radiation, immunodeficiency and increased cancer incidence. A patient with...

Activity of paclitaxel in radiation induced and other secondary angiosarcomas

10578 Background: Angiosarcomas (AS) represent 1–2% of adult soft tissue sarcomas and can arise anywhere in the body. Major predisposing factors are therapeutic radiation and chronic lymphedema. Paclitaxel has shown an exceptionally high activity of 75–89% in angiosarcomas of the face and scalp and to a lesser and less consitent degree of 15–58% in other disease locations. We report on a retrospectice single center experience with chemotherapy in 17 patients (pts.) with secondary angiosarcomas (SAS). Methods: Data from 17 patients were analysed including 15 females and 2 males with a median age of 63 years (range 18–80 years). 12 female patients suffered from angiosarcoma of the breast/thoracic wall following operation and radiation + chemotherapy of a primary breast cancer with an interval of a median of 6 years (range 2–15 years). 1 patient developed a SAS 6 years after resection and radiation of a liposarcoma in the limb. 4 patients were diagnosed with SAS following chronic lymphedema (3 Steward-Treves-Syndrome, interval 8, 9 and 38 years, repectively and 1 connatal lymphedema, interval 18 years). Results: 14/17 pts. received surgery as first treatment for SAS. 10 pts. developed a locoregional recurrence, 1 pt. distant metastases. 3 pts. remain free of disease. 3 pts. were diagnosed with locally advanced/metastatic SAS. Surgery for local recurrence after primary surgery resulted in further recurrence in all cases. All 14 patients with recurrent/metastatic disease were treated with chemotherapy. 12 pts. received paclitaxel at a dose of 175 mg/m2 q3w or 50–70 mg/m2 q1w as first- or second-line therapy. Responses were 8 PR with a median PFS of 6 months (range 3–23 months), and 1 SD (PFS 4 months) with a disease control rate of 75%. 2 pts. are too early to evaluate, 1 pt. showed PD. In only 3/11 cases, pts. responded to Anthracycline-based chemotherapy. Conclusions: Paclitaxel shows high activity in SAS, comparable to the results in face and scalp angiosarcomas and can be considered a standard treatment option. No significant financial relationships to disclose.